Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab Intensification Before allo-HSCT in MRD-Negative B-ALL
NCT07003737Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Feb 2025
- Primary completion
- Feb 2027
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Randomised trial of blinatumomab in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Relapse-Free Survival at 2 years. Started Feb 2025; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07003737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07003737.